Literature DB >> 15034940

Low doses and high doses of heparin have different effects on osteoblast-like Saos-2 cells in vitro.

Heinz-Juergen Hausser1, Rolf E Brenner.   

Abstract

Long-term treatment with heparin has been associated with an increased risk of osteoporosis. Given the importance of heparan sulfate proteoglycans for bone metabolism, it can be anticipated that heparin due to its structural similarity with heparan sulfate chains somehow interferes with the biological activities of these cell surface- and extracellular matrix-associated molecules. Initially in order to study the effect(s) of heparin on osteoblasts that possibly contribute to the development of heparin-induced osteoporosis, we treated osteoblast-like Saos-2 cells in monolayer culture for different periods of time with different concentrations of heparin. None of the heparin concentrations tested led to an inhibition of osteoblast proliferation during the early proliferative phase. After longer incubation times, however, cultures treated with higher concentrations of heparin (>/=5 microg/ml) exhibited a reduction in cell number as well as an inhibition of matrix deposition and mineralization. These effects could not be observed with lower heparin concentrations. On the contrary, low concentrations of heparin (5-500 ng/ml) even promoted matrix deposition and its subsequent mineralization. Apparently, heparin has a biphasic effect on osteoblast-like Saos-2 cells, being inhibitory at high concentrations but stimulatory at low concentrations. These results imply that heparin at concentrations well below those used for antithrombotic therapy might eventually turn out to be beneficial for bone formation. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15034940     DOI: 10.1002/jcb.20007

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  Disruption of cell-matrix interactions by heparin enhances mesenchymal progenitor adipocyte differentiation.

Authors:  Weijun Luo; Hailu Shitaye; Michael Friedman; Christina N Bennett; Joshua Miller; Ormond A Macdougald; Kurt D Hankenson
Journal:  Exp Cell Res       Date:  2008-07-12       Impact factor: 3.905

2.  The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing.

Authors:  Kambiz Sarahrudi; Georg Kaiser; Anita Thomas; Mark Michel; Harald Wolf; Mehdi Mousavi; Seyedhossein Aharinejad
Journal:  Int Orthop       Date:  2011-10-29       Impact factor: 3.075

3.  Enhanced control of in vivo bone formation with surface functionalized alginate microbeads incorporating heparin and human bone morphogenetic protein-2.

Authors:  Sunny Akogwu Abbah; Jing Liu; James Cho Hong Goh; Hee-Kit Wong
Journal:  Tissue Eng Part A       Date:  2012-11-07       Impact factor: 3.845

4.  High xylosyltransferase activity in children and during mineralization of osteoblast-like SAOS-2 cells.

Authors:  Christian Prante; Joachim Kuhn; Knut Kleesiek; Christian Götting
Journal:  Glycoconj J       Date:  2008-09-02       Impact factor: 2.916

5.  Heparin regulates colon cancer cell growth through p38 mitogen-activated protein kinase signalling.

Authors:  G Chatzinikolaou; D Nikitovic; A Berdiaki; A Zafiropoulos; P Katonis; N K Karamanos; G N Tzanakakis
Journal:  Cell Prolif       Date:  2009-10-21       Impact factor: 6.831

6.  Heparin microparticle effects on presentation and bioactivity of bone morphogenetic protein-2.

Authors:  Marian H Hettiaratchi; Tobias Miller; Johnna S Temenoff; Robert E Guldberg; Todd C McDevitt
Journal:  Biomaterials       Date:  2014-05-28       Impact factor: 12.479

7.  Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization.

Authors:  V Shalhoub; S C Ward; B Sun; J Stevens; L Renshaw; N Hawkins; W G Richards
Journal:  Calcif Tissue Int       Date:  2011-06-03       Impact factor: 4.333

8.  A Blood Bank Standardized Production of Human Platelet Lysate for Mesenchymal Stromal Cell Expansion: Proteomic Characterization and Biological Effects.

Authors:  Andrea Bianchetti; Clizia Chinello; Michele Guindani; Simona Braga; Arabella Neva; Rosanna Verardi; Giovanna Piovani; Lisa Pagani; Gina Lisignoli; Fulvio Magni; Domenico Russo; Camillo Almici
Journal:  Front Cell Dev Biol       Date:  2021-05-14

9.  The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells.

Authors:  Emma Luong-Van; Lisbeth Grøndahl; Shujun Song; Victor Nurcombe; Simon Cool
Journal:  J Mol Histol       Date:  2007-08-11       Impact factor: 3.156

10.  Antiproliferative Properties of Scandium Exopolysaccharide Complexes on Several Cancer Cell Lines.

Authors:  Javier Muñoz-Garcia; Mattia Mazza; Cyrille Alliot; Corinne Sinquin; Sylvia Colliec-Jouault; Dominique Heymann; Sandrine Huclier-Markai
Journal:  Mar Drugs       Date:  2021-03-23       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.